Anticoagulant therapy--1974.
D000208:Acute Disease; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000517:prevention & control; D003374:Coumarins / Q000627:therapeutic use; D005112:Extracorporeal Circulation / Q000009:adverse effects; D005260:Female; D006354:Heart, Artificial / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D002542:Intracranial Embolism and Thrombosis / Q000517:prevention & control; D008297:Male; D008833:Microcirculation; D009203:Myocardial Infarction / Q000517:prevention & control; D010973:Platelet Adhesiveness; D011517:Prothrombin Time; D011655:Pulmonary Embolism / Q000517:prevention & control; D012214:Rheumatic Heart Disease / Q000517:prevention & control; D013924:Thrombophlebitis / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D014481:United States
D000925:Anticoagulants; D003374:Coumarins; D006493:Heparin